Bicycle Therapeutics is a UK biotech developing highly constrained bicyclic peptides (bicycles) as a novel class of therapeutic
Bicycles have the affinity and specificity associated with antibodies, but are much smaller in size and can be chemically synthesised. They have been shown to address targets not easily tractable with small molecules (e.g. protein-protein interactions).The company is exploring applications in a number of areas where these advantageous features have the potential to show significant benefit.
Bicycle Therapeutics is backed by top-tier VC investors and is seeking to realise the full potential of Bicycle technology by developing an internal pipeline of bicycles into the clinic, as well as allowing partners access to the technology platform through selected R&D collaborations.
Press Release 21 September 2015
Bicycle Therapeutics announces appointment of CEO More
Press Release 11 May 2015
Bicycle Therapeutics announces appointment of President & CBO More
Press Release 14 October 2014
Bicycle Therapeutics announces £20M ($32M) million financing for drug development More
Press Release 5 September 2013 Bicycle Therapeutics and ThromboGenics form an alliance to develop bicycle peptide inhibitors for the treatment of ophthalmic diseases More
Press Release 1 June 2013 Bicycle Therapeutics announces expansion of management team with appointments of CSO and Business Development Director More
Press Release 10 Dec 2012 Bicycle Therapeutics announces £3.75 million financing for drug discovery More
FMC 2015 Symposium
(Frontiers in Medicinal Chemistry)
14-16 September, 2015
Presenting: Christophe Bonny